Fairfield, Bush & Co’s Bristol-Myers Squibb BMY Stock Holding History

Fairfield, Bush & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,886	Closed	-$237K	–	112
2025 Q1	$237K	Buy	+3,886	New	+$227K	0.15%	99
2024 Q1	–	Sell	-1,835	Closed	-$94.2K	–	154
2023 Q4	$94.2K	Buy	+1,835	New	+$96.3K	0.06%	157
2023 Q3	–	Sell	-23,535	Closed	-$1.51M	–	150
2023 Q2	$1.51M	Buy	23,535 +2,700	+13%	+$181K	0.41%	55
2023 Q1	$1.44M	Buy	+20,835	New	+$1.47M	0.51%	48
2022 Q3	–	Sell	-2,635	Closed	-$203K	–	152
2022 Q2	$203K	Sell	2,635 -340	-11%	-$25.9K	0.12%	117
2022 Q1	$217K	Sell	2,975 -1,200	-29%	-$80.6K	0.11%	120
2021 Q4	$260K	Sell	4,175 -19,100	-82%	-$1.12M	0.13%	116
2021 Q3	$1.38M	Buy	23,275 +1,240	+6%	+$81.7K	0.45%	55
2021 Q2	$1.47M	Sell	22,035 -3,138	-12%	-$205K	0.4%	53
2021 Q1	$1.59M	Hold	25,173	–	–	0.45%	51
2020 Q4	$1.56M	Hold	25,173	–	–	0.46%	51
2020 Q3	$1.52M	Sell	25,173 -200	-0.8%	-$12K	0.48%	50
2020 Q2	$1.49M	Sell	25,373 -700	-3%	-$41.9K	0.53%	49
2020 Q1	$1.45M	Sell	26,073 -561	-2%	-$34.3K	0.6%	40
2019 Q4	$1.71M	Buy	26,634 +9,335	+54%	+$535K	0.63%	41
2019 Q3	$877K	Buy	17,299 +4,450	+35%	+$209K	0.3%	70
2019 Q2	$583K	Sell	12,849 -150	-1%	-$6.99K	0.2%	88
2019 Q1	$620K	Sell	12,999 -2,125	-14%	-$106K	0.21%	88
2018 Q4	$786K	Sell	15,124 -4,159	-22%	-$223K	0.27%	78
2018 Q3	$1.2M	Buy	19,283 +2,900	+18%	+$172K	0.34%	60
2018 Q2	$907K	Sell	16,383 -3,808	-19%	-$206K	0.27%	70
2018 Q1	$1.28M	Sell	20,191 -664	-3%	-$42.7K	0.37%	55
2017 Q4	$1.28M	Buy	20,855 +3,059	+17%	+$191K	0.35%	57
2017 Q3	$1.13M	Buy	17,796 +1,250	+8%	+$73K	0.35%	56
2017 Q2	$922K	Buy	16,546 +4,725	+40%	+$257K	0.3%	60
2017 Q1	$643K	Sell	11,821 -30	-0.3%	-$1.65K	0.2%	77
2016 Q4	$693K	Hold	11,851	–	–	0.23%	77
2016 Q3	$639K	Sell	11,851 -220	-2%	-$14.1K	0.21%	83
2016 Q2	$888K	Sell	12,071 -250	-2%	-$17.7K	0.31%	57
2016 Q1	$787K	Sell	12,321 -100	-0.8%	-$6.31K	0.28%	62
2015 Q4	$854K	Sell	12,421 -18,568	-60%	-$1.23M	0.3%	66
2015 Q3	$1.83M	Sell	30,989 -9,650	-24%	-$612K	0.81%	36
2015 Q2	$2.7M	Sell	40,639 -2,375	-6%	-$157K	0.81%	41
2015 Q1	$2.77M	Sell	43,014 -2,500	-5%	-$157K	0.81%	40
2014 Q4	$2.69M	Buy	45,514 +55	+0.1%	+$3.1K	0.77%	43
2014 Q3	$2.33M	Buy	45,459 +110	+0.2%	+$5.5K	0.67%	45
2014 Q2	$2.2M	Buy	45,349 +38,524	+564%	+$1.9M	0.65%	45
2014 Q1	$355K	Buy	6,825 +495	+8%	+$26.3K	0.17%	79
2013 Q4	$336K	Sell	6,330 -34,550	-85%	-$1.76M	0.15%	82
2013 Q3	$1.89M	Sell	40,880 -8,820	-18%	-$387K	0.57%	51
2013 Q2	$2.22M	Buy	+49,700	New	+$2.16M	1.13%	21

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fairfield, Bush & Co's BMY Position: Q2 2025 in Review

Fairfield, Bush & Co sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 3,886 shares — an estimated $237K sold.

Fairfield, Bush & Co first reported a position in BMY in Q2 2013 and held it in 41 quarters. The position peaked at $2.77M in Q1 2015. 2,293 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

Fairfield, Bush & Co reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
Fairfield, Bush & Co sold 3,886 Bristol-Myers Squibb shares in Q2 2025, an estimated $237K.
Fairfield, Bush & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 41 quarters.
Fairfield, Bush & Co's Bristol-Myers Squibb position peaked at $2.77M in Q1 2015.
2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Fairfield, Bush & Co's 13F filing for Q2 2025, filed 15 Aug 2025.